Premium
Cancer‐Cell‐Specific Nuclear‐Targeted Drug Delivery by Dual‐Ligand‐Modified Mesoporous Silica Nanoparticles
Author(s) -
Xiong Lin,
Du Xin,
Kleitz Freddy,
Qiao Shi Zhang
Publication year - 2015
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.201501056
Subject(s) - nanocarriers , mesoporous silica , hela , cancer cell , nanoparticle , drug delivery , doxorubicin , ligand (biochemistry) , chemistry , targeted drug delivery , biophysics , drug , nanotechnology , cell , materials science , cancer , mesoporous material , pharmacology , receptor , biochemistry , medicine , biology , chemotherapy , surgery , catalysis
Mesoporous silica nanoparticles are modified with dual targeting ligands, i.e., folic acid and dexamethasone, to construct a cancer‐cell‐specific nuclear‐targeted delivery system. The resulting nanocarriers can not only enhance the inhibition efficacy of doxorubicin on Hela cells through active nucleus accumulation but also reduce toxic side effects on noncancer cells though receptor‐mediated selective cellular uptake.